Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Division of Child Neurology and Inherited Metabolic Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Brain. 2023 Aug 1;146(8):3273-3288. doi: 10.1093/brain/awad039.
In the field of rare diseases, progress in molecular diagnostics led to the recognition that variants linked to autosomal-dominant neurodegenerative diseases of later onset can, in the context of biallelic inheritance, cause devastating neurodevelopmental disorders and infantile or childhood-onset neurodegeneration. TOR1A-associated arthrogryposis multiplex congenita 5 (AMC5) is a rare neurodevelopmental disorder arising from biallelic variants in TOR1A, a gene that in the heterozygous state is associated with torsion dystonia-1 (DYT1 or DYT-TOR1A), an early-onset dystonia with reduced penetrance. While 15 individuals with AMC5-TOR1A have been reported (less than 10 in detail), a systematic investigation of the full disease-associated spectrum has not been conducted. Here, we assess the clinical, radiological and molecular characteristics of 57 individuals from 40 families with biallelic variants in TOR1A. Median age at last follow-up was 3 years (0-24 years). Most individuals presented with severe congenital flexion contractures (95%) and variable developmental delay (79%). Motor symptoms were reported in 79% and included lower limb spasticity and pyramidal signs, as well as gait disturbances. Facial dysmorphism was an integral part of the phenotype, with key features being a broad/full nasal tip, narrowing of the forehead and full cheeks. Analysis of disease-associated manifestations delineated a phenotypic spectrum ranging from normal cognition and mild gait disturbance to congenital arthrogryposis, global developmental delay, intellectual disability, absent speech and inability to walk. In a subset, the presentation was consistent with foetal akinesia deformation sequence with severe intrauterine abnormalities. Survival was 71%, with higher mortality in males. Death occurred at a median age of 1.2 months (1 week-9 years), due to respiratory failure, cardiac arrest or sepsis. Analysis of brain MRI studies identified non-specific neuroimaging features, including a hypoplastic corpus callosum (72%), foci of signal abnormality in the subcortical and periventricular white matter (55%), diffuse white matter volume loss (45%), mega cisterna magna (36%) and arachnoid cysts (27%). The molecular spectrum included 22 distinct variants, defining a mutational hotspot in the C-terminal domain of the Torsin-1A protein. Genotype-phenotype analysis revealed an association of missense variants in the 3-helix bundle domain to an attenuated phenotype, while missense variants near the Walker A/B motif as well as biallelic truncating variants were linked to early death. In summary, this systematic cross-sectional analysis of a large cohort of individuals with biallelic TOR1A variants across a wide age-range delineates the clinical and genetic spectrum of TOR1A-related autosomal-recessive disease and highlights potential predictors for disease severity and survival.
在罕见病领域,分子诊断学的进展使得人们认识到,与常染色体显性神经退行性疾病相关的变体在双等位基因遗传的情况下,可能导致毁灭性的神经发育障碍和婴儿期或儿童期发病的神经退行性疾病。TOR1A 相关多发性先天性关节挛缩症 5(AMC5)是一种罕见的神经发育障碍,由 TOR1A 的双等位基因变体引起,在杂合状态下与扭转痉挛 1(DYT1 或 DYT-TOR1A)相关,这是一种发病早、外显率低的肌张力障碍。尽管已经报道了 15 名 AMC5-TOR1A 患者(不到 10 名详细报道),但尚未对完整的疾病相关谱进行系统调查。在这里,我们评估了 40 个家系中 57 名 TOR1A 双等位基因变异个体的临床、放射学和分子特征。最后一次随访时的中位年龄为 3 岁(0-24 岁)。大多数患者表现为严重的先天性屈曲挛缩(95%)和不同程度的发育迟缓(79%)。79%的患者报告有运动症状,包括下肢痉挛和锥体束征,以及步态障碍。面部畸形是表型的一个组成部分,主要特征是宽/全鼻尖、额头变窄和脸颊饱满。对疾病相关表现的分析描绘了一个表型谱,从正常认知和轻度步态障碍到先天性关节挛缩、全面发育迟缓、智力残疾、无言语和无法行走。在一部分患者中,表现与严重宫内异常的胎儿运动不能变形序列一致。存活率为 71%,男性死亡率较高。死亡发生在中位年龄 1.2 个月(1 周-9 岁),原因是呼吸衰竭、心脏骤停或败血症。脑 MRI 研究分析确定了非特异性神经影像学特征,包括胼胝体发育不全(72%)、皮质下和脑室周围白质信号异常灶(55%)、弥漫性白质体积丢失(45%)、大枕大池(36%)和蛛网膜囊肿(27%)。分子谱包括 22 个不同的变体,定义了 Torsin-1A 蛋白 C 末端结构域的突变热点。基因型-表型分析显示,3 螺旋束结构域的错义变异与减弱的表型相关,而靠近 Walker A/B 基序的错义变异以及双等位基因截断变异与早期死亡相关。总之,这项对 22 个不同变体的大样本双等位基因 TOR1A 变体的跨年龄范围的系统横断面分析,描绘了 TOR1A 相关常染色体隐性疾病的临床和遗传谱,并强调了疾病严重程度和存活的潜在预测因素。